The prof also said that MACE of p=0.036 is enough to ask for FDA approval at phase 3 (!!) Re T2D he also spoke about C-reactive protein (CRP) being the major risk factor for heart attack and death in patients with T2D. Many T2D drug trials have fallen over due to increasing CRP, and the FDA quickly cottoned on to msb trial showing reduced CRP in line with dosage to "cardio-protective" levels. He also said they're in discussions with various potential partners in addition to teva and to expect a lot more news flow.
The prof also said that MACE of p=0.036 is enough to ask for FDA...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |